• Trends from the Trenches: The Capability Jump of AI and Its Impact

    Bio-IT World | A year ago, some would have said AI was not making an impact on drug development or computational biology. But Sonia Timberlake, R&D strategy consultant at Timberlake & Maclsaac Biopharma Consulting, argues that recent rapid innovation makes it hard to claim AI isn’t impacting computational biology anymore.

    May 7, 2026

  • Bacteria: Unsung Players in the Tumor Microbiome

    Bio-IT World | How cancer patients will respond to treatment can be anticipated based on their genetics as well as the tumor microenvironment, although one relevant component is often all but dismissed: the tumor microbiota. This is despite an abundance of evidence that a cancer’s microbial community plays a major role not only in therapeutic effects but also in tumor development, progression, and metastasis formation.

    May 6, 2026

  • Much Progress Needed Planning Research to Consider Sex as a Biological Variable

    Bio-IT World | In 2016, the National Institutes of Health (NIH) introduced a policy requiring grantees to consider sex as a biological variable in their experimental design, analyses, and reporting. Now a team from Northwestern University has assessed progress, highlighting significant room for improvement.

    May 5, 2026

  • Craig Venter, Genomics Pioneer and Visionary, Dies

    Bio-IT World | The J. Craig Venter Institute (JCVI) announced that J. Craig Venter, Ph.D., the Institute’s founder, board chair, and chief executive officer, died yesterday in San Diego following a brief hospitalization for unexpected side effects that arose from treatment of recently diagnosed cancer. He was 79

    Apr 30, 2026

  • Follow the Money: Autoimmune, Inflammatory Disease Therapies, Antibody-Drug Conjugates, AKT1-Selective Inhibitor Programs

    Bio-IT World | Beeline Medicines debuts and advances a differentiated pipeline of precision therapies; Syneron Bio advances proprietary macrocyclic peptide discovery platform, Synova; Terremoto Biosciences advances lead AKT1-selective inhibitor programs through phase 1 clinical development; and more.

    Apr 30, 2026